Stockwinners Market Radar for November 04, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:26 EDT DraftKings CEO: Right in line on where we thought we'd be with user growth - In an interview on CNBC's Mad Money, Jason Robins said he's "very pleased" with DraftKings' user growth. The company is doing a good job simultaneously pursuing top line growth and cost efficiencies, he noted. "We're a young public company and we have a lot to prove," he added.

18:01 EDT Gelesis receives NYSE notice of non-compliance - Gelesis Holdings noted that the company received a notification letter from the New York Stock Exchange advising that because the average closing price of the company's common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual. The company's common stock will continue to be listed and traded on the NYSE, subject to the company's compliance with other NYSE continued listing standards. The company will provide a timely response to the NYSE's letter to confirm its intent to return to compliance.

17:33 EDT Tuesday Morning CEO Fred Hand to retire, Andrew Berger to succeed - Tuesday Morning announced the following leadership changes, effective immediately: Andrew Berger appointed CEO. Berger who brings over 25 years of consumer industry experience succeeds current CEO, Fred Hand, who decided to retire from his roles at the company as CEO and member of the Board. Berger will continue to serve on the company's Board. Bill Baumann, Chief Information and Chief Marketing Officer, appointed COO. Baumann succeeds Marc Katz who served as COO and interim CFO, who has decided to retire. The company has already initiated a comprehensive search process to identify a permanent CFO. Andrew Berger will assume CFO and finance responsibilities in the interim. Paul Metcalf, Principal and Chief Merchant has decided to retire. Bill Baumann will assume responsibilities as Chief Merchant in the interim. Hand, Katz and Metcalf will consult with the company to ensure a smooth transition through June 30, 2023.

17:15 EDT Lockheed Martin awarded $765.15M Navy contract - Lockheed Martin was awarded a not-to-exceed $765.16M firm-fixed-price, cost-plus-fixed-fee, undefinitized indefinite-delivery/indefinite-quantity contract. This contract provides for site activation/hardware requirements in support of first aircraft arrival, initial operation capability, and full operational capability milestone events, to include site activation events, support equipment, pilot flight equipment, and post ejection survival training material, as well as contract management, planning and readiness reviews and associated non-recurring introduction to service activities in support of F-35A, F-35B, and F-35C aircraft initial sustainment activities for the Air Force, Marine Corps, Navy, non-Department of Defense participants and Foreign Military Sales customers. Work is expected to be completed in December 2024. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to 10 U.S. Code 2304. The Naval Air Systems Command is the contracting activity.

16:46 EDT Red River Bancshares renews share repurchase program - Red River Bancshares announced that its board of directors approved the renewal of its stock repurchase program, which will expire on December 31, 2022. The repurchase program authorizes the company to purchase up to $5M of its outstanding shares of common stock from January 1, 2023 through December 31, 2023.

16:38 EDT Vertiv Holdings director Deangelo acquires 71,600 class A shares - In a regulatory filing, Vertiv Holdings director Joseph Deangelo disclosed the purchase of 71,600 class A common shares of the company on November 3 at a price of $13.99 per share.

16:35 EDT NYSE, Indonesia Stock Exchange to collaborate on joint product development - The New York Stock Exchange, part of Intercontinental Exchange, and the Indonesia Stock Exchange, or IDX, announced that they have agreed to collaborate on several areas of mutual interest, including joint product development. The NYSE and the IDX signed a memorandum of understanding that also included opportunities for promoting both markets, information and knowledge sharing, and establishing new communication channels. The agreement was finalized during a visit to the NYSE by an Indonesian delegation that included Hon. Iman Rachman, president director of the Indonesia Stock Exchange, H.E. Rosan Roeslani, Ambassador of Indonesia to the United States and Arifi Saiman, Consul General of Indonesia in New York.

16:17 EDT Hepsiburada receives Nasdaq notification over minimum bid price - Hepsiburada announced that on November 3, 2022 it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the bid price for the company's American depositary shares, each representing one Class B ordinary share of the company, had closed below the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules. Based on the closing bid price of the company's ADSs for the last 30 consecutive business days, the company has failed to meet the Minimum Bid Requirement for continued listing on the Nasdaq Global Select Market set forth in Listing Rule 5450(a)(1) during that period. The Notice is only a notification that the company is not in compliance with the Minimum Bid Requirement, it is not a notice of imminent delisting, and it has no immediate effect on the listing or trading of the company's ADSs on the Nasdaq Global Select Market. Pursuant to Listing Rule 5810(c)(3)(A), the company has 180 calendar days from the date of the Notice, or May 2, 2023, to regain compliance with the Minimum Bid Requirement, during which time the ADSs will continue to trade on the Nasdaq Global Select Market. The company may regain compliance with the Minimum Bid Requirement if at any time before May 2, 2023, the bid price of the ADSs closes at or above $1.00 per ADS for a minimum of 10 consecutive business days.

16:06 EDT Brooge Energy receives Nasdaq staff determination letter - Brooge Energy announced that it has received a staff determination letter from The Nasdaq Stock Market dated October 31, 2022. The company intends to request a hearing before a Nasdaq Hearings Panel at which it will request a further extension of time. The hearing request will automatically stay any suspension or delisting action through November 22, 2022; however, in connection with the hearing request, the company will request that the Nasdaq stay remain in effect through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. In the event the extended stay is not granted, the company will continue to trade on the OTC Markets Expert Market under the same symbol "BROG." As previously disclosed on a Form 6-K filed by the company on May 23, 2022, the company received a letter from Nasdaq notifying the company that it is not in compliance with the Nasdaq's requirements under the timely filing criteria pursuant to Nasdaq Listing Rule 5250(c)(1) as a result of the company not having been able to timely file its annual report on Form 20-F for the year ended December 31, 2021, with the Securities and Exchange Commission. The Nasdaq Staff subsequently granted the company a compliance period of 180 calendar days, or until October 28, 2022, to regain compliance with the Filing Rule. On October 31, 2022, the company received the Letter from Nasdaq notifying the company of the determination of the Nasdaq staff that because the company had not regained compliance with the Filing Rule by timely filing the 2021 Form 20-F, unless the Company timely requests a hearing, its securities would be subject to delisting. Accordingly, as noted above, the Company intends to timely request a hearing. While the Staff's authority to grant an extension was limited to 180 calendar days from the due date for the late filing, pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant an extension up to 360 days from the due date for the late filing.

15:44 EDT Rocket Lab says successfully deployed 152nd satellite - Rocket Lab USA reports it has successfully launched its 32nd Electron mission to deploy its 152nd satellite to orbit, a science payload for the Swedish National Space Agency. The MATS satellite was deployed to its 585km circular orbit by Electron following lift-off at 17:27 UTC. "The "Catch Me If You Can" mission also resulted in a successful ocean splashdown of the Electron rocket's first stage. Rocket Lab had planned to attempt amid-air capture of Electron's first stage with a helicopter if conditions allowed, however not all requirements were met to ensure a successful capture. Due to a brief telemetry loss with Electron's first stage during its atmospheric re-entry, the helicopter was moved out of the capture zone per standard safety procedure. The Electron first stage completed a safe splashdown and Rocket Lab's recovery vessel is now alongside the stage to bring it onboard and back to Rocket Lab's production facility for inspection and analysis," the company stated in a press release. "Bringing a rocket back from space is a challenging task and capturing it mid-air with a helicopter is as complex as it sounds. The chances for success are much smaller than that of failure because many complex factors that must perfectly align. We are proud to have successfully recovered our fifth rocket from the ocean now and we look forward to another mid-air capture attempt in future as we work toward making Electron a reusable rocket," added Rocket Lab founder and CEO, Peter Beck.

15:27 EDT Novo Nordisk purchases B shares worth DKK 3.582B from Novo Holdings - Novo Nordisk announced it has entered into an agreement to purchase 4,207,500 B shares of DKK 0.20 at a value of DKK 3.582B from Novo Holdings A/S. "The transaction is part of Novo Nordisk A/S' 2022 share repurchase programme of up to a total of DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. The transaction price is DKK 851.26 per share and has been calculated as the three-day volume weighted average market price from 2 November 2022 to 4 November 2022 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk A/S was 28.2% of the share capital and 77.0% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 102,104,000 B shares of DKK 0.20, corresponding to 28.1% of the capital and 76.9% of the votes in Novo Nordisk A/S. The transaction is in line with the announcement on 2 November that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S' share capital around 28%. With the transactions stated above, Novo Nordisk A/S owns a total of 27,443,142 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total number of A and B shares in the company is 2,280,000,000 of DKK 0.20 including treasury shares," the company stated.

14:26 EDT AMV Stock trading resumes

13:25 EDT Venus Acquisition Corp trading resumes

13:17 EDT SeaStar Medical Holding Corp trading halted, volatility trading pause

13:05 EDT Venus Acquisition Corp trading halted, volatility trading pause

12:57 EDT Wolverine World Wide names Tom Long as lead independent director - Wolverine World Wide announced the appointment of Nicholas T. "Tom" Long as Lead Independent Director of its Board of Directors, effective November 4, 2022. Long, a Wolverine Worldwide director since 2011 and current chair of the Compensation Committee, succeeds Dr. David T. Kollat, who will remain on the Board. "We are very pleased to announce Tom's appointment as our next Lead Independent Director," said Brendan Hoffman, Wolverine Worldwide's President and CEO.

12:00 EDT Telephone and Data falls -26.7% - Telephone and Data is down -26.7%, or -$4.43 to $12.14.

12:00 EDT HireRight falls -37.4% - HireRight is down -37.4%, or -$4.76 to $7.98.

12:00 EDT MediaAlpha rises 22.5% - MediaAlpha is up 22.5%, or $2.53 to $13.78.

11:51 EDT Theseus Pharmaceuticals Inc trading resumes

11:19 EDT Perfumania Holdings, Inc. trading resumes

11:13 EDT FDA doesn't see bebtelovimab neutralizing Omicron subvariants BQ.1, BQ.1.1 - The FDA announced that it has updated the Health Care Provider Fact Sheet for bebtelovimab with specific information regarding expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2. "This information shows that bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. At this time, bebtelovimab remains authorized in all U.S. regions until further notice by FDA... There areseveral treatmentsthat are authorized or approved to treat certain patients with mild-to-moderate COVID-19 which are expected to retain activity against currently circulating variants, including Omicron subvariants BQ.1 and BQ.1.1... Health care providers should assess whether these treatments are right for their patient in the event the patient develops mild-to-moderate COVID-19," the FDA update stated. An Emergency Use Authorization authorizes bebtelovimab, manufactured by Eli Lilly and Company, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. Reference Link

10:33 EDT Eli Lilly reports EMPA-KIDNEY phase 3 clinical trial met primary endpoint - The EMPA-KIDNEY phase 3 clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease, or CKD, Eli Lilly announced. When treated with Jardiance, the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo. The results were announced today during the American Society of Nephrology's, or ASN, Kidney Week 2022 by the Medical Research Council Population Health Research Unit at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company. The results were also published simultaneously in The New England Journal of Medicine. "EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a significant reduction in all-cause hospitalizations vs. placebo, one of the pre-specified key secondary confirmatory endpoints," the company noted. The overall safety data was generally consistent with previous findings, "confirming the well-established safety profile of Jardiance," Eli Lilly added.

10:06 EDT Chinook Therapeutics presents data from BION-1301, CHK-336 programs - Chinook Therapeutics announced two posters on the BION-1301 and CHK-336 programs being presented at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida. FR-PO659 - Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy" BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 2 clinical development for patients with IgAN. Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1/ Updated data from Cohort 1 and initial data from Cohort 2 were presented from Part 3 of the ongoing phase 1/2 multi-center trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical responses of open-label BION-1301 treatment in patients with IgAN. Key highlights from the presentation include the following: Patients in Cohort 1 initially received a 450mg intravenous dose of BION-1301 every two weeks. After at least 24 weeks of IV dosing, patients in Cohort 1 transitioned to a 600 mg SC dose every two weeks for a total treatment duration of up to two years. Cohort 1 enrolled 10 patients, of which eight patients remain on treatment. All eight patients have transitioned from IV to SC administration, with a mean SC treatment duration of 40 weeks. Patients in Cohort 2 are receiving a SC dose of 600 mg of BION-1301 every two weeks for a total treatment duration of up to two years. Cohort 2 has enrolled 24 of the planned 30 patients. Mean treatment duration was 17 weeks, with time on treatment ranging from two to 30 weeks. Baseline 24-hour Urine Protein Excretion: The median baseline 24-hour urine protein excretion for patients enrolled in Cohort 1 was 1.2 g/day, with a range of 0.7 - 6.5 g/day, and the median baseline 24-hour urine protein excretion for patients enrolled in Cohort 2 was 1.0 g/day, with a range of 0.6 - 2.7 g/day. Cohorts 1 and 2 both represent a population of patients with IgAN at high risk of kidney disease progression. Safety and Tolerability As of the October 13, 2022 data cutoff, BION-1301 has been well-tolerated, with no serious adverse events or treatment discontinuations due to adverse events. Of all 34 patients enrolled in both Cohorts 1 and 2: Eight patients experienced mild treatment-related AEs, including three patients with fatigue and three patients with injection site reactions. Seventeen patients experienced mild infections, of which only one Grade 1 infection was assessed as treatment-related. The PK profile demonstrated low inter-individual variability in BION-1301 serum concentrations and consistent trough concentrations following IV and SC administrations. To date, no anti-drug antibodies have been observed in patients. BION-1301's effects on mechanistic biomarkers were highly consistent between Cohorts 1 and 2. In Cohort 1, reductions in IgA and Gd-IgA1 were maintained beyond 52 weeks of treatment. Reductions in IgM, and to a lesser extent IgG, were also observed. Reductions in free APRIL confirm durable target neutralization sustained through one year. In Cohort 2, SC BION-1301 treatment resulted in rapid and sustained reductions in IgA and Gd-IgA1, IgM, and to a lesser extent IgG, through 24 weeks of treatment, consistent with Cohort 1. In Cohort 1, BION-1301 demonstrated mean reductions in 24-hour urine protein creatinine ratio of 30.4% in seven patients at 12 weeks of treatment, 48.8% in all eight patients at 24 weeks of treatment, 66.9% in all eight patients at 52 weeks of treatment, 67.4% in four patients at 76 weeks of treatment and 71.0% in two patients at 100 weeks of treatment. Clinically meaningful reductions in UPCR from baseline were seen in patients with IgAN across a wide range of baseline proteinuria levels by Week 12. UPCR continued to decline through one year, and reductions were maintained through two years, providing evidence of sustained efficacy. Among patients with available data at Week 52, seven of eight patients demonstrated a greater than 50% mean reduction in 24-hour UPCR from baseline at Week 52. In Cohort 2, BION-1301 demonstrated mean reductions in 24-hour UPCR of 28.7% in 15 patients at 12 weeks of treatment and 53.8% in 9 patients at 24 weeks of treatment, highly consistent with reductions observed at the same timepoints in Cohort 1. FR-PO334 - Preclinical Efficacy of CHK-336: A First in Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxalurias: CHK-336 is a potent LDHA inhibitor with liver-targeted tissue distribution that is efficacious in PH1 and PH2 mouse models and has potential benefit in non-genetic hyperoxalurias caused by oxalate overproduction. CHK-336 demonstrates potent inhibition of LDHA in enzyme assays and primary hepatocyte assays across multiple species. CHK-336 also demonstrates tight LDHA binding with a very slow off-rate. CHK-336 exhibits a liver-targeted tissue distribution profile in mice, rats and monkey with high liver concentrations and low extra-hepatic tissue exposures. Since LDHA catalyzes the final step of oxalate production from glycolate, in vivo conversion of a 13C2-glycolate stable isotope tracer to 13C2-oxalate was dose-dependently blocked by CHK-336, demonstrating target engagement. Human PK predictions suggest CHK-336 has the potential to be a low, once-daily oral dose therapeutic in humans. CHK-336 was dosed orally, once-daily for seven days in male Agxt KO mice, a PH1 mouse model, and urinary oxalate concentrations were compared to a vehicle control group. Low, oral, once-daily doses of CHK-336 significantly and dose-dependently reduced urinary oxalate; the majority of treated mice reached the normal range observed in wild-type mice. CHK-336 also had a more rapid onset of action and comparable magnitude of urinary oxalate reduction compared to a GO-targeting siRNA. CHK-336 was dosed orally, once-daily for seven days at 25 mg/kg in male Grhpr KO mice, a PH2 mouse model, and significantly reduced urinary oxalate concentrations compared to the vehicle control group. Increased urinary oxalate and altered hepatic expression of genes involved in oxalate synthesis were observed in obese, hypertensive and diabetic rats compared to controls. This supports the potential therapeutic benefit of CHK-336 in non-genetic oxalate nephropathies associated with increased endogenous production of oxalate. The human safety and PK profiles of CHK-336 are currently under investigation in a phase 1 healthy volunteer SAD/MAD study and data is expected to be presented in the first half of 2023. Administration of the 13C2-glycolate stable isotope tracer has been incorporated into the phase 1 study to assess LDHA target engagement in humans.

10:00 EDT Unifi falls -29.0% - Unifi is down -29.0%, or -$2.73 to $6.68.

10:00 EDT Orion Engineered rises 15.9% - Orion Engineered is up 15.9%, or $2.44 to $17.80.

10:00 EDT Perimeter Solutions rises 19.6% - Perimeter Solutions is up 19.6%, or $1.40 to $8.56.

09:47 EDT Protolabs falls -15.7% - Protolabs is down -15.7%, or -$5.61 to $30.10.

09:47 EDT Yamana Gold rises 18.4% - Yamana Gold is up 18.4%, or 75c to $4.83.

09:47 EDT Full Truck Alliance rises 23.3% - Full Truck Alliance is up 23.3%, or $1.20 to $6.35.

09:40 EDT Digimarc trading resumes

09:40 EDT Definitive Healthcare trading resumes

09:39 EDT Funko trading resumes

09:34 EDT Funko trading halted, volatility trading pause

09:32 EDT Pulmonx Corp trading halted, volatility trading pause

09:31 EDT Digimarc trading halted, volatility trading pause

09:30 EDT Definitive Healthcare trading halted, volatility trading pause

09:22 EDT Pan American Silver, Agnico Eagle make binding offer for Yamana Gold - Pan American Silver (PAAS) and Agnico Eagle Limited (AEM) are pleased to announce that we have delivered a definitive binding offer to the board of directors of Yamana Gold (AUY) pursuant to which Pan American would acquire all of the issued and outstanding common shares of Yamana and Yamana would sell certain subsidiaries and partnerships which hold Yamana's interests in its Canadian assets to Agnico Eagle, including the Canadian Malartic mine. The transaction shall be implemented by way of a plan of arrangement under the Canada Business Corporations Act. The consideration consists of 153,539,579 common shares in the capital of Pan American; $1B in cash contributed by Agnico Eagle; and 36,089,907 common shares in the capital of Agnico Eagle. Under the Binding Offer, each Yamana Share would be exchanged for approximately $1.04 in cash, 0.1598 Pan American Shares and 0.0376 Agnico Eagle Shares, for an aggregate value of $5.02 per Yamana Share based on the closing price of each Pan American Share and Agnico Eagle Share on November 3. The Binding Offer is not subject to any financing condition or additional due diligence. Pan American and Agnico Eagle have been informed that Yamana's Board of Directors, in consultation with Yamana's financial and legal advisors, have determined that the Binding Offer constitutes a "Yamana Superior Proposal" as defined in the arrangement agreement dated May 31, 2022 between Yamana and Gold Fields Limited (GFI) and that Yamana has notified Gold Fields of its intention to accept the Binding Offer, subject only to Gold Fields' "right to match" under the Gold Fields Agreement. The completion of the Arrangement will also be subject to regulatory approvals and closing conditions customary in transactions of this nature. The agreement governing the Arrangement will provide for customary deal-protection provisions, including mutual non-solicitation covenants and rights to match superior proposals. The Arrangement Agreement will include a reciprocal termination fee of $250M, payable by Yamana to Pan American, or $375M payable from Pan American to Yamana, as the case may be, under certain circumstances. The Arrangement would close late in the first quarter of 2023.

09:19 EDT Xponential Fitness signs master franchise agreement in Portugal for Club Pilates - Xponential Fitness announced it has signed a master franchise agreement in Portugal for its Club Pilates brand. The agreement, signed with Porto-based Mitrinha & Libelinha gives the master franchisee the opportunity to license a minimum of 20 Club Pilates studios in Portugal over the next 10 years. The Master Franchise partners bring extensive experience scaling globally-recognized consumer retail brands in Portugal.

09:18 EDT Quhuo appoints Marcum Asia CPAs as accounting firm - Quhuo announced the appointment of Marcum Asia CPAs as the Company's independent registered public accounting firm, effective from October 31. On the same date, the Company dismissed Ernst & Young Hua Ming, or EY. The change of the Company's independent auditor was made after careful consideration and evaluation process and was approved by the audit committee of the board of directors and the Board. EY's audit reports on the Company's consolidated financial statements as of and for the years ended December 31, 2021 and 2020 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. The Company is working closely with MarcumAsia and EY to ensure a seamless transition. The Company would like to take this opportunity to express its sincere gratitude to the EY team for their professionalism and quality of services rendered to the Company over the past years.

09:12 EDT Eos Energy selected for energy storage project in California - Eos Energy Enterprises announced an order for a 35 MWh energy storage system capable of 10-hour discharge duration. The order, worth $13.5 million, is funded by a grant through the CEC's Long-Duration Energy Storage Program as part of a project being carried out by Indian Energy, a 100 percent Native American-owned business, to create a first-of-its-kind resilient clean energy microgrid. A long-term service agreement is expected to be signed by Eos and Indian Energy in the coming weeks.

09:02 EDT Borqs Technologies' HHE launches HoluPower xP energy storage system - Borqs Technologies (BRQS) announced its subsidiary, Holu Hou Energy, HHE, has rolled out its next generation HoluPower xP energy storage system. The HoluPower xP building on the leading attributes of the HoluPower series product, specifically delivers: A safer lithium ion battery chemistry; More system power; Greater system modularity; Higher power for each battery module; Energy control through the HHE Modular Energy Control platform; Integrated home load control; Standard wired internet connection, with optional WiFi or cellular communications; Better system conversion efficiency; Faster installation times with an almost 50% reduction in wiring terminations; and The industry's only single-family Residential energy storage system economically viable for unlocking the Multi-Dwelling Unit Residential market.

08:50 EDT Syneos Health no longer expects to achieve 7%-10% revenue growth in FY23 - The company said on its Q3 earnings conference call that it no longer expects to achieve the 7%-10% revenue growth for FY23 it previously predicted, and it also doesn't anticipate achieving its targeting 30-50bps of annual adjusted EBITDA margin expansion. Syneos anticipates providing formal 2023 guidance "early next year."

08:37 EDT Vitalhub acquires certain assets to maintain business of ADI health - VitalHub announced that it has acquired certain assets to maintain the business of Advanced Digital Innovation Limited trading as "ADI Health" with the product widely known as "MyPathway". The assets were sold to two of VitalHub's wholly-owned subsidiaries, MyPathway Solutions Limited and Intouch with Health Limited after ADI Health was placed into Administration by its directors after over GBP 3 million pound sterling had been invested into the development of the technology since 2020. VitalHub will be making various payments totalling approximately GBP 250,000 in cash to complete the transaction. The transaction includes seven NHS customers across England and Wales novated to Intouch, who will ensuring there is no interruption to existing services. The seven customers represent an annualized recurring revenue of GBP 373,609. Not included in the previous ARR figure is professional services work that was historically billed to customers and will continue to be offered. Six of the employees along with other services were transferred to VitalHub to ensure continuance of services.

08:35 EDT Jupiter Wellness announces approval of Photocil for sale in India - Jupiter Wellness announced that its Photocil product has been approved by the CDSCO for sale in India. The Central Drugs Standard Control Organisation, under the Directorate General of Health Services, Ministry of Health & Family Welfare, is the National Regulatory Authority of India. Photocil is a topical product that filters UV rays from the sun to allow only the therapeutic UV spectrum to penetrate the skin. It is used for the treatment of psoriasis and vitiligo.

08:26 EDT CDPQ supports KKR's acquisition of Albioma SA - Global investment group CDPQ announced that it has provided part of the EUR 485M acquisition financing to support the friendly tender offer launched by KKR & Co. to acquire 100% of Albioma SA, a French independent renewable energy producer. CDPQ is the main lender in the transaction, alongside other commercial lenders and banks.

08:17 EDT Dragonfly names Nicole Harvey as CLO, Wade Seaburg as CRO, Tyler Bourns as CMO - Dragonfly Energy Holdings announced several executive level promotions to support its strategic initiatives. The promotions will be effective immediately, and these executives will join CFO John Marchetti, in providing leadership across all key functions of the company. Nicole Harvey has been promoted to Chief Legal Officer, responsible for the company's corporate law and governance, intellectual property, government relations, risk management and corporate compliance functions. Ms. Harvey joined Dragonfly in 2021, bringing more than 14 years of legal and compliance experience through her various roles in public and private practice. Wade Seaburg has been promoted to Chief Revenue Officer, responsible for Dragonfly's sales, business development and revenue growth and diversification efforts. Seaburg began working with Dragonfly in 2018. Tyler Bourns has been promoted to Chief Marketing Officer. Mr. Bourns joined Dragonfly in 2021 and brings more than 15 years of sustained success producing award-winning content for global brands

08:14 EDT Aligos Therapeutics presents data for its Capsid Assembly Modulator - Aligos Therapeutics will deliver a poster presentation at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases, AASLD. The poster highlights clinical data for its small molecule capsid assembly modulator-empty capsid drug candidate, ALG-000184, which is in development for the treatment of chronic hepatitis B. The poster includes the following key results from the ongoing Phase 1 study ALG-000184-201 in HBeAg-positive CHB cohorts that received 28 daily oral doses of ALG-000184 at either the 100 mg or 300 mg dose levels: ALG-000184 reduced hepatitis B surface antigen levels in a subset of HBeAg-positive subjects; among 7 subjects with evaluable HBsAg data who were treated with 300 mg ALG-000184, 3 subjects experienced reductions in HBsAg levels of 0.2-0.8 log10 IU/mL; One subject in the 100 mg ALG-000184 cohort experienced a reduction in HBsAg levels of 0.5 log10 IU/mL; Rapid and profound reductions in hepatitis B virus DNA and RNA were observed in all subjects; HBV DNA mean decline: 4.2, 4.0 log10 IU/mL; HBV RNA mean decline: 3.1, 2.6 log10 copies/mL. "We are excited about these preliminary data on the most advanced candidate in Aligos' CHB portfolio," said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. "While this dataset is small and needs to be confirmed, the observed reductions in viral surface antigen over such a short duration with an oral treatment have not been seen before. Combined with the potent reductions in HBV DNA and RNA, these new data indicate that ALG-000184 may have best-in-class antiviral properties. Based on these data, we have initiated additional cohorts in this study to confirm these observations and explore the impact of treatment for up to 48 weeks on HBsAg levels."

08:13 EDT Aligos Therapeutics presents data for its NASH program, Hepatitis B portfolio - Aligos Therapeutics announced that the company is presenting several posters and an oral presentation at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases, AASLD. Notably, poster 2354 provides new data on the activity of ALG-055009, Aligos' thyroid hormone receptor beta agonist in development for nonalcoholic steatohepatitis. Multiple ascending dose data from the ongoing Phase 1 study ALG-055009-301 demonstrate that treatment for 14 days in subjects with hyperlipidemia resulted in reduced triglyceride, low-density lipoprotein, and apolipoprotein B levels in a generally dose-dependent manner. ALG-055009 was well tolerated and resulted in favorable dose-proportional pharmacokinetics with low inter-subject variability across the therapeutic range. "We are pleased with the emerging clinical profile of ALG-055009," said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. "THR-beta agonists continue to have the potential to become a cornerstone therapy in the treatment of NASH and ALG-055009 appears to benchmark favorably with other drugs in this class. Moving forward, we plan to evaluate its ability to reduce fat in the livers of subjects with NASH over a twelve-week period in a Phase 2 study funded internally or through a partnership."

08:11 EDT Terns Pharmaceuticals highlights results from Phase 1 trial of TERN-501 - Terns Pharmaceuticals announced that the company is presenting positive clinical data from its Phase 1 study of TERN-501, a thyroid hormone receptor beta agonist in development for the treatment of NASH. The results are being highlighted in a poster presentation at The Liver Meeting(R), the annual meeting of the American Association for the Study of Liver Diseases, AASLD, taking place November 4-8, 2022. The poster presentation highlights results from a Phase 1 study in which healthy participants with low-density lipoprotein, LDL, cholesterol levels of 100-190 mg/dL were randomized to receive TERN-501 or placebo once daily for 14 days. Results showed that among the 24 treated participants TERN-501 was generally well tolerated and exhibited dose-dependent pharmacokinetics with low variability. TERN-501-treated participants also experienced increases in sex-hormone binding globulin, a key pharmacodynamic marker of THR-beta engagement linked to decreases in levels of atherogenic lipids and NASH histologic efficacy, which were time- and dose-dependent and highly associated with TERN-501 exposure. "The data presented from our Phase 1 study reiterate that TERN-501 has a predictable pharmacokinetic profile with low variability and treatment results in robust SHBG increases and lipid-lowering effects. TERN-501 is a promising candidate for NASH treatment, either as a monotherapy or in combination with other agents," said Kerry Russell, M.D., Ph.D., chief medical officer at Terns. "We look forward to continued assessments of TERN-501 including our ongoing Phase 2a DUET trial of TERN-501, alone and in combination with our FXR agonist TERN-101, with top-line data anticipated in the second half of 2023."

08:10 EDT DMG Blockchain Solutions mines 82 bitcoin in October - DMG Blockchain Solutions announces October preliminary mining results. In October 2022, DMG mined 82 bitcoin with 0.72 EH/s realized hashrate. DMG's bitcoin balance as of October 31, 2022 was 346 bitcoin. Although there has been a shipping delay for its September batch of miners, DMG still expects to grow its hashrate to 1 EH/s by the end of calendar 2022, subject to the receipt, installation and operation of the additional miners.

08:09 EDT American Axle says 'not engaged in any discussions to sell the company' - "AAM is aware of the media activity regarding the company on November 3rd. While our long-standing policy is to not publicly comment on market rumors and media speculation, we feel it is important to state that we are not engaged in any discussions to sell the company and that we are not otherwise for sale. In the ordinary course of executing on our strategic plan, we continuously monitor market conditions and assess industry developments and we regularly consider strategic opportunities that serve the best interests of the company (including our customers and associates) and its shareholders. AAM does not intend to make any further comment or respond to any inquiries unless or until it determines that further disclosure is appropriate or necessary."

08:07 EDT CymaBay presents additional analyses from studies of seladelpar - CymaBay Therapeutics announced encouraging seladelpar data in patients with primary biliary cholangitis that are being presented at The Liver Meeting(R) of the American Association for the Study of Liver Diseases, in Washington, DC. In a clinical poster presentation titled "Seladelpar Improved the Lipid Profile of Patients with Primary Biliary Cholangitis: Results from Phase 2 and 3 Clinical Studies" Christopher L. Bowlus MD, the chief of the Division of Gastroenterology and Hepatology at the University of California Davis, will be reporting the results of a pooled analysis from an open-label phase 2 study and a placebo controlled phase 3 study assessing the efficacy, safety, and tolerability of seladelpar at a daily dose of 5 mg or 10 mg in PBC patients who had an inadequate response or an intolerance to ursodiol. A second poster presenting clinical data titled "Seladelpar, a PPAR-delta Agonist, Improves Inflammatory Lipid Mediators in the Serum Metabolome in Patients with Primary Biliary Cholangitis" will reveal that seladelpar treatment in patients with PBC resulted in broad changes in serum metabolomics. Seladelpar increased mitochondrial and peroxisomal fatty acid oxidation and significantly reduced levels of inflammatory lipid mediators. Finally, a preclinical poster presentation titled "Effects of Single and Multiple Doses in Mice of the Selective PPAR-delta Agonist Seladelpar on Diurnal Markers of Bile Acid Synthesis" will examine the effects of light cycle and food intake as important time-of-day variables that impact bile acid synthesis.

08:05 EDT Ayala Pharmaceuticals announces upcoming milestones - Continue enrollment in Phase 3 of the RINGSIDE trial: Part B, the Phase 3 portion of the RINGSIDE trial, is a double-blind placebo-controlled study enrolling up to 156 patients with progressive desmoid disease, randomized between AL102 or placebo. The primary endpoint is Progression Free Survival with secondary endpoints including objective response rates, duration of response, and patient-reported quality of life measures. A poster featuring the interim data from Part A of RINGSIDE has been selected for presentation at the Connective Tissue Oncology Society 2022 Annual Meeting, taking place November 16-19 in Vancouver, Canada. Gain clarity from U.S FDA on the registration path for AL101 in recurrent/metastatic adenoid cystic carcinoma, expected in early 2023; Expected closing of merger with Advaxis, by the end of Q1 2023, subject to approval by Ayala's shareholders and the satisfaction of customary closing conditions; Present longer-term data from Part A of RINGSIDE with AL102, expected in mid-2023.

08:01 EDT Kratos Defense sees 'difficult operating environment' for 'foreseeable future' - Kratos stated last night: "On October 1, 2022, the U.S. Federal Government began operating under a Continuing Resolution Authorization - CRA - through at least December 16, 2022, with no Federal Fiscal 2023 Budget or DoD budget being in place. Under a CRA, federal spending and its composition is substantially held consistent with the previous year's budget, with no new contract awards, no increased production or spending on existing programs and no transition from development to production contracts, or from low-rate initial production to full rate production being allowed, all of which may impact Kratos and our current fourth quarter and fiscal 2023 financial expectations. The longer a CRA period is extended, the greater the impact on the industry, our customers and Kratos. Throughout the third and fourth quarter of 2022, our industry and Kratos continue to experience the effects of continuing supply chain disruptions and significant cost increases and inflation, including on our employees, consultants, subcontractors, vendors, suppliers, customers, etc., and an acute labor shortage of qualified personnel, including those requiring security clearances, to perform on programs and contracts. We expect this difficult operating environment and its impact on the industry, our operations and our ability to forecast to continue for the foreseeable future."

07:46 EDT American Axle selected as new axle supplier by General Motors - American Axle & Manufacturing (AXL) announced it has been selected as the new axle supplier for GM's (GM) next generation mid-size pickup trucks. The new vehicles will debut for model year 2023. "AAM is pleased to expand our partnership with GM as the new supplier of axles for GM's next generation mid-size pickup trucks. We look forward to providing our latest and most efficient driveline technologies for the Chevrolet Colorado and GMC Canyon," said AAM Chairman and CEO. Axles supporting this additional truck program will be built at AAM's Three Rivers Manufacturing Facility in Michigan.

07:39 EDT Berkshire Hills Bancorp raises quarterly dividend 50% to 18c from 12c per share - Berkshire Hills Bancorp announced that its Board of Directors has approved a quarterly cash dividend of 18c per common share to shareholders of record at the close of business on November 17, payable on December 1.

07:33 EDT AnPac Bio granted continued listing by NASDAQ hearing panel - AnPac Bio-Medical Science announced that on October 31, 2022, the Company has been notified by the Nasdaq Hearings Panel of the Listing Qualifications Department of The Nasdaq Stock Market that the Company's request for continued listing on The Capital Market has been granted, subject to the following: On or before November 23, 2022, the Company shall demonstrate compliance with Listing Rule 5550(a)(2), the $1 Bid Price Rule. In order to fully comply with the terms of this exception, the Company must be able to demonstrate compliance with all requirements for continued listing on The Nasdaq Stock Market. In the event the Company is unable to do so, its securities may be delisted from The Nasdaq Stock Market. The decision was made by the Nasdaq Hearings Panel following a hearing held on October 20, 2022, during which the Company presented its plan to regain compliance with $1 Bid Rule. In the meantime, the Company will continue to be listed and its shares will continue to be traded on Nasdaq, pending a final written decision by the Nasdaq Hearings Panel after November 23, 2022.

07:32 EDT DoorDash sees Q4 marketplace GOV $13.9B-$14.2B - Sees Q4 adjusted EBITDA $85M-$120M. The company states: "Among other things, our Q4 outlook anticipates a consumer spending environment that is consistent with recent months. It also anticipates significant levels of ongoing investment in new categories and international markets. Our forecast assumes key foreign currency rates remain stable at current levels."

07:23 EDT Ondas' American Robotics enters technology partnership with Infrared Cameras - Ondas Holdings announced American Robotics' strategic technology partnership with Infrared Cameras. Combined with ICI's optical gas imaging and thermal sensors, American Robotics' autonomous Scout System drone will be equipped with the technology needed to automate inspection of oil and gas assets and identification of methane leaks.

07:16 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted 14 newly-hired employees stock options to purchase an aggregate of 125,700 shares, and restricted stock units covering an aggregate of 46,350 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2022 as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.35 per share, which is equal to the closing price of BioCryst common stock on the grant date.

07:14 EDT Broadwind appoints Shivaram to board of directors - Broadwind announced the appointment of Sachin Shivaram to its Board of Directors, effective November 2, 2022. Shivaram brings to Broadwind more than fourteen years of strategic leadership experience. Since 2019, Shivaram has served as chief executive officer of Wisconsin Aluminum Foundry, a vertically integrated provider of aluminum and copper-based alloy castings for a wide variety of industries.

07:13 EDT Auddia announces departure of Chief Financial Officer - Auddia announced the departure of its Chief Financial Officer, CFO, Brian Hoff. Hoff is leaving the Company to join a private equity backed manufacturing company, as CFO. Auddia's Board of Directors has approved an outside firm to support financial reporting and serve as fractional CFO effective upon Hoff's departure. The Company has also launched a formal search process to identify a new CFO.

07:11 EDT Medicenna Therapeutics announces anticipated milestones - Expected Upcoming Milestones: New safety, pharmacokinetic, and pharmacodynamic data from the ABILITY study's first four dose escalation cohorts will be presented next week at the Society for Immunotherapy of Cancer's 37th Annual Meeting. Updated anti-tumor activity data from the ABILITY study's escalation cohorts are expected in calendar Q1-2023. Early anti-tumor activity data from the ABILITY study's single agent expansion phase are expected in mid-2023. Early anti-tumor activity data from the ABILITY study's combination arm are expected in Q4-2023.

07:09 EDT Immunovant announces anticipated milestones - Batoclimab: A Phase 2b trial in CIDP is planned to be initiated by the end of calendar year 2022, with initial results expected in the first half of calendar year 2024. In Graves' disease, a Phase 2 trial is planned to be initiated in early calendar year 2023 with initial results expected in the second half of calendar year 2023. Immunovant plans to finalize the lead asset and trial design in WAIHA following an expected engagement with the hematology division of the FDA before the end of calendar year 2022. As previously disclosed, Immunovant expects to have top-line results from the MG trial in the second half of calendar year 2024 and expects to have top-line results from the two TED trials in the first half of calendar year 2025. IMVT-1402:This next generation FcRn inhibitor was unveiled in September. Immunovant plans to submit an Investigational New Drug application for IMVT-1402 in early calendar year 2023 with an expected initial data readout in mid-calendar year 2023.

07:05 EDT Cboe Global Markets to launch trading in Mini S&P 500 Index options - Cboe Global Markets announced plans to launch trading in Mini S&P 500 Index options during global trading hours, which will make the product available to customers nearly 24 hours every business day on Cboe Options Exchange, beginning December 11.

06:57 EDT Aecom's JV selected for Glassboro-Camden Line Light Rail project in New Jersey - Aecom's South Jersey Transit Partners joint venture with STV Inc. has been selected by the Glassboro-Camden Line - GCL - Project Team to provide engineering, project management, and additional professional services for the GCL Light Rail project in New Jersey. The planned 18-mile corridor will restore passenger service along an existing rail line. The GCL Project Team is managed by the Delaware River Port Authority - DRPA - with partners NJ Transit and the South Jersey Transportation Authority. The joint venture's scope is anticipated to encompass preliminary engineering, program management, civil and structural engineering, track design, risk management, quality assurance, schedule and cost management, permitting and environmental review, and operational and communication systems.

06:43 EDT GrafTech sees steel industry outlook "volatile" - GrafTech provided an outlook, stating: "the current environment for the steel industry remains volatile with key markets, such as Europe, continuing to experience weakening demand as broader macroeconomic conditions deteriorate. Steel industry trends have also softened somewhat in the U.S., although the market remains comparatively healthy and more stable. As a result, we expect graphite electrode demand to remain soft in the fourth quarter of 2022 and into 2023 reflecting market dynamics, which continue to be dictated by geopolitical conflict and economic uncertainty. At the same time, as is the case for nearly all industries, costs remain elevated for raw materials, energy and logistics. Due to the current inflationary environment, we anticipate sequential cost increases to continue in 4Q22. In addition to the efforts to resolve the situation involving our Monterrey, Mexico facility, we are aligning operating and capital expenditures with the current environment as we remain committed to maintaining a strong balance sheet. Longer term, we remain confident that the steel industry's accelerating efforts to decarbonize will lead to increased adoption of the electric arc furnace method of steelmaking, driving long-term demand for graphite electrodes. The actions we are taking will optimally position GrafTech to benefit from that long-term growth. In addition, our vertical integration into petroleum needle coke production via our Seadrift facility is a critical differentiator from our competitors and foundational for our ability to reliably deliver high-quality graphite electrodes".

06:35 EDT Cinemark to open seven new theatres, 55 screens subsequent to 2022 - As of September 30, the company's aggregate screen count was 5,835, and the company had commitments to open two new theatres and 19 screens during the remainder of 2022 and seven new theatres and 55 screens subsequent to 2022.

06:21 EDT Jabil says Kenny Wilson to succeed Mark Mondello as CEO on May 1, 2023 - Jabil announced that Kenny Wilson has been named as the company's next CEO and will continue to work closely with Mark Mondello, Jabil's current Chairman and CEO, before assuming the role of CEO on May 1, 2023. Mondello, a Jabil employee for more than 30 years, will continue to serve as Executive Chairman following the effective date of Wilson's appointment. Wilson joined the company in 2000 and has admirably delivered for Jabil, on assignments in Europe, Asia and the Americas. Most recently, he has held the title of Executive Vice President, successfully leading the Jabil Greenpoint Team.

06:13 EDT TuanChe signs strategic cooperation with Beijing S-TECH Technology - TuanChe recently signed a strategic cooperation agreement with Beijing S-TECH Technology. S-TECH is a research-based technology company, specializing in bespoke vehicle research, development and design, as well as automotive parts development and manufacturing. The partnership will allow both parties to leverage their respective resource advantages and prioritize each other's needs. The two companies will explore the potential for the application of S-TECH's technologies and products to assist TuanChe's model development as part of the Company's strategic expansion into the new energy vehicle market. The strategic cooperation agreement represents another step forward for TuanChe to bolster its core automotive development team with industry alliances, enabling the Company to expedite its time to market and enhance the market positioning and competitiveness of its vehicles.

05:22 EDT Albertsons issues statement regarding restraint of special dividend - Albertsons (ACI) announced that the Attorney General of the State of Washington has been granted a temporary restraining order, or TRO, by a Commissioner assistant to the judge. The TRO restrains the company from paying the previously announced $6.85 per common share special dividend, originally scheduled to be paid on November 7. The order enables the court to consider the merits at a hearing scheduled for November 10. The order remains in effect until November 10, unless within that time, an order is entered extending or dismissing the TRO. Albertsons intends to seek to overturn the restraint as quickly as possible because the temporary order was based on the incorrect assertion that payment of the special dividend would impair its ability to compete while its proposed merger with Kroger (KR) is under antitrust review. A hearing on the State of Washington's request for a preliminary injunction is scheduled for November 10. Albertsons Cos. continues to maintain that the lawsuit brought by the State of Washington, and the similar lawsuit brought by the Attorneys General of California, Illinois, and the District of Columbia are meritless and provide no legal basis for canceling or postponing a dividend that has been duly and unanimously approved by Albertsons Cos.' fully informed board of directors. The company said, "The Company's plan to return capital to stockholders is part of its long-stated capital-return strategy and does not change the fact that Albertsons Cos. is in the strongest financial position it has ever been. The Company remains fully committed to investing in the associates, stores, and digital capabilities that have made its recent growth and strong performance possible. Albertsons Cos. is confident that it will continue to make strategic progress following the payment of the Special Dividend, given its strong cash flows and low debt profile. After payment of the Special Dividend, Albertsons Cos. will have approximately $3.0 billion of liquidity, including approximately $500 million in cash and approximately $2.5 billion available under its already existing asset-based lending facility, and expects to continue to generate strong revenues and positive free cash flow, furthering increasing liquidity. Albertsons Cos. intends to argue vigorously based on the factual record that there is simply no basis to continue restraining the payment of the Special Dividend."